Italian venture capital firm Innogest Capital named Giovanni Leo as partner.
A serial entrepreneur and successful innovator in the global medtech space, Leo joined Innogest in 2017 as venture partner.
His role now scales into the investment team, strengthening the healthcare practice toward international excellence.
Prior to Innogest, Leo was Vice President of Research & Development at St Jude Medical since the acquisition (€330M) in 2013 of Endosense, the company he co-founded to develop a novel technology for the catheter ablation treatment of cardiac arrhythmias.
Formerly, he was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy.
Leo was also co-founder of Isotopes and Metals Ltd., a medical device company focused on technology for prostate and gynecological brachytherapy.
He previously held a software quality manager position at LeCroy Corp. as well as a CERN fellowship to carry out development activity for the control system of the Large Hadron Collider (LHC).
Led by Claudio Giuliano, partner and founder, Innogest is a venture capital firm based in Turin, Milan, Geneva and San Francisco.
It currently manages about €200 million of capital, investing in Digital and Life sciences innovative companies.